Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186328 · ClinicalTrials.gov registry record · Phase 1
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
A Phase 1 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01186328 is a Phase 1 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 6 participants.
The verdict
NCT01186328, a Phase 1 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.
Interventions
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Prednisone
- DRUG Cytarabine
- DRUG EZN-3042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-08-24 |
| Est. Completion | 2012-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186328
The ClinicalTrials.gov registry entry for NCT01186328 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT01186328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01186328 about?
NCT01186328 is a clinical study titled "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)". An experimental drug called EZN-3042 targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. The main goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combinatio...
What is the current status of trial NCT01186328?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2010-08-24. Estimated completion is 2012-01-10.
What interventions are being tested in trial NCT01186328?
The interventions under investigation include: Doxorubicin (DRUG), Vincristine (DRUG), Prednisone (DRUG), Cytarabine (DRUG), EZN-3042 (DRUG).
Who is sponsoring clinical trial NCT01186328?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.